| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T50688 | ||||
| Target Name | Glycoprotein IIb/IIIa receptor | ||||
| Target Type | Successful |
||||
| Drug Potency against Target | Eptifibatide | Drug Info | Kd = 120 nM/L | [552191] | |
| Abciximab | Drug Info | KD = 8.5+/-5.6 nM/L | [553277] | ||
| Tirofiban | Drug Info | Kd = 15 nM/L | [552191] | ||
| References | |||||
| Ref 552191 | Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation. 1999 Jul 27;100(4):437-44. | ||||
| Ref 553277 | Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation. 1998 Sep 15;98(11):1085-91. | ||||
| Ref 552191 | Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation. 1999 Jul 27;100(4):437-44. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.